Saks Fifth Avenue and Saturday Night Live Partner to Celebrate SNL’s 40th season, and the 16th Year of Key to the Cure

Cast members of Saturday Night Live, entering its 40th season this fall, are promoting the 16th year of Saks Fifth Avenue’s “Key to the Cure,” locally benefiting women’s cancer research at the Translational Genomics Research Institute (TGen).

During Key to the Cure‘s Oct. 16-19 charity-shopping weekend, Saks Fifth Avenue at Biltmore Fashion Park, 2446 E. Camelback Road, will donate 2 percent of sales to support breast and ovarian cancer research at TGen.

The highpoint of the Saks Phoenix fundraising shopping spree is the signature Key to the Cure fashion show, starting at 8:30 a.m. Oct. 17, featuring gourmet food, drinks, a raffle for designer items, and an exclusive peak at the latest fashions. For more information, please visit: www.tgenfoundation.org/events, or contact Andrea Kobielski at akobielski@tgen.org or 602-343-8572.

“We are honored to be Saks’ long-term partner for Key to the Cure, and excited about the visibility and awareness that Saturday Night Live’s past and current cast members bring to women’s cancers,” said Erin Massey, Vice President of Development for Cancer Programs for the TGen Foundation. “Locally, Key to the Cure highlights TGen’s patient-focused breast and ovarian cancer research initiatives and provides our scientists funding to pursue new and innovative research.”

Current Saturday Night Live cast members (Vanessa Bayer, Cecily Strong and Colin Jost) and past cast members (Will Ferrell and Ana Gasteyer) are this year’s Entertainment Industry Foundation (EIF) ambassadors for Saks Fifth Avenue’s 2014 Key to the Cure campaign.

The SNL cast members will appear in national public service announcements wearing a limited-edition unisex tee created by celebrated New York designers Marcus Wainwright and David Neville of rag & bone. The Key to the Cure PSA will appear in major fashion and lifestyle magazines in September and October.

The shirt will retail for $35 at Saks Fifth Avenue stores and online at saks.com and saksoff5th.com. All — 100 percent — of the proceeds from each shirt sold will be donated to TGen, benefiting charitable programs dedicated to finding new detection methods, better treatments and eventual cures for women’s cancers. The tee debuts Oct. 1 at Saks Fifth Avenue.

In the past 15 years since the inception of the Saks Fifth Avenue charity-shopping weekend, the retailer has raised more than $35 million for cancer research.

In addition to the partnership for the annual Key to the Cure campaign, Saks Fifth Avenue will sell exclusive merchandise inspired by notable Saturday Night Live characters from seven New York designers. These items, curated by Saturday Night Live’s Emmy-nominated costume designer Tom Broecker, will be available in Saks Fifth Avenue’s New York flagship store and on saks.com during the Key to the Cure shopping weekend.

The merchandise includes: Mango’s shorts as interpreted by Alexander Wang, The Nerds outfit as interpreted by Alice + Olivia, a dress fit for The Californians as interpreted by Diane von Furstenberg, Spartans Cheerleading uniforms as interpreted by Elizabeth and James, hats fit for The Coneheads as interpreted by Eugenia Kim, Mary Katherine Gallagher’s school uniform as interpreted by rag & bone, and Gilly’s dress as interpreted by Suno.

About Saks Fifth Avenue
Saks Fifth Avenue, one of the world’s pre-eminent specialty retailers, is renowned for its superlative American and international designer collections, its expertly edited assortment of handbags, shoes, jewelry, cosmetics and gifts, and the first-rate fashion expertise and exemplary client service of its Associates. As part of the Hudson’s Bay Company brand portfolio, Saks operates 39 full-line stores in 22 states, five international licensed stores, 73 Saks Fifth Avenue OFF 5TH stores and saks.com, the company’s online store. Saks Fifth Avenue is proud to be named a J.D. Power and Associates 2012 Customer Service Champion and is only one of 50 U.S. companies so named.

About TGen
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Advertisements

TGen Receives Approval for Patient Enrollment in Brain Cancer Clinical Trial

Catherine Ivy and Dr. David Craig

 

Glioblastoma (GBM) Pilot Trial funded by Ivy Foundation

In 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute (TGen). One of those projects has officially received the final regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can begin.

 

In the $5-million-project, “Genomics Enabled Medicine in Glioblastoma Trial,” TGen and its clinical partners will lead first-in-patient clinical trial studies that will test promising new drugs that might extend the survival of GBM patients. This multi-part study will take place in clinics across the country and TGen laboratories.

 

“GBM is one of the top three fastest-killing cancers out there and it affects people of all ages,” said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation. “It is critical that we fund research that will help patients live longer so we can study and treat brain cancer.”

 

The project begins with a pilot study of 15 patients, using whole genome sequencing to study their tumor samples to help physicians determine what drugs might be most beneficial.

 

To support molecularly informed clinical decisions, TGen labs also will examine genomic data from at least 536 past cases of glioblastoma, as well as tumor samples from new cases, developing tools that will produce more insight into how glioblastoma tumors grow and survive. TGen also will conduct a series of pioneering lab tests to measure cell-by-cell responses to various drugs.

 

“GBM is a disease that needs answers now, and we strongly believe those answers will be found in the genome,” said Dr. David Craig, TGen’s Deputy Director of Bioinformatics, Director of TGen’s Neurogenomics Division, and one of the projects principal investigators. “Identifying the genes that contribute to the survival of glioblastoma will provide valuable information on how to treat it, and may also lead to an improved understanding of what drives other cancers as well.”

 

To get new treatments to patients as quickly as possible, this five-year study will include a feasibility study involving up to 30 patients, followed by Phase II clinical trials with as many as 70 patients. TGen is teaming with the Ivy Early Phase Clinical Trials Consortium that includes: University of California, San Francisco; University of California, Los Angeles; the MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Utah; and the Dana-Farber/Harvard Cancer Center.

 

The results of these clinical trials should not only help the patients who join them, but also provide the data needed for FDA approval and availability of new drugs that could benefit tens of thousands of brain cancer patients in the future.

 

“Working with physicians, the project will aim to understand treatment in the context of the tumor’s molecular profile. We will have the opportunity to determine when combinations of drugs might be more effective than using a single drug, quickly identify which therapies don’t work, and accelerate discovery of ones that might prove promising for future development,” said Dr. John Carpten, TGen’s Deputy Director of Basic Science, Director of TGen’s Integrated Cancer Genomics Division, and another of the project’s principal investigators.

 

In addition to helping patients as quickly as possible, the project should significantly expand Arizona’s network of brain cancer experts.

 

About The Ben & Catherine Ivy Foundation

The Ben & Catherine Ivy Foundation, based in Scottsdale, Ariz., was formed in 2005, when Ben Ivy lost his battle with glioblastoma multiforme (GBM).  Since then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.  The Ben & Catherine Ivy Foundation is the largest privately funded foundation of its kind in the United States.  For more information, visit http://www.ivyfoundation.org. We have regular updates via social media – please find us on:

Blog:  Ivy Foundation http://www.IvyFoundation.wordpress.com

Facebook:  Ivy Foundation  http://www.facebook.com/IvyFoundation

Twitter:  @IvyFoundation https://twitter.com/IvyFoundation

Google+:   Ivy Foundation https://plus.google.com/105982076267406579679/posts

LinkedIn:  Ivy Foundation http://linkedin.com/company/the-ben-and-catherine-ivy-foundation

YouTube:  IvyFoundationGBM http://www.youtube.com/user/IvyFoundationGBM

 

About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.